A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma

NCT02093000 · clinicaltrials.gov ↗

COMPLETED

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Adenocarcinoma

Interventions

DRUG: Bevacizumab

Sponsor

Hoffmann-La Roche